Petter Björquist
Direttore/Membro del Consiglio presso PHASE HOLOGRAPHIC IMAGING PHI AB
Profilo
Petter Björquist is currently the Chief Executive Officer at NovaHep AB, Chief Executive Officer at Verigraft AB, and Director at Phase Holographic Imaging AB, Stimuliver ApS, and ATMP Sweden.
Previously, he was the Vice President-Regenerative Medicine at Takara Bio Europe AB from 2002 to 2014.
Posizioni attive di Petter Björquist
| Società | Posizione | Inizio |
|---|---|---|
| PHASE HOLOGRAPHIC IMAGING PHI AB | Direttore/Membro del Consiglio | - |
NovaHep AB
 NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | Amministratore Delegato | - |
Verigraft
 Verigraft BiotechnologyHealth Technology Verigraft engages in the development of personalized human tissues for transplantation. The company is headquartered in Gothenburg, Sweden. | Amministratore Delegato | 01/02/2014 |
Precedenti posizioni note di Petter Björquist
| Società | Posizione | Fine |
|---|---|---|
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Corporate Officer/Principal | 01/01/2014 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PHASE HOLOGRAPHIC IMAGING PHI AB | Health Technology |
| Aziende private | 3 |
|---|---|
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Commercial Services |
NovaHep AB
NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | Commercial Services |
Verigraft
Verigraft BiotechnologyHealth Technology Verigraft engages in the development of personalized human tissues for transplantation. The company is headquartered in Gothenburg, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Petter Björquist
